Single-dose, Open-label, Randomized, 4-way Crossover Study to Compare 10 mg of an Oral Suspension of Rivaroxaban Under Fasting (2 Different Batches) and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Bayer
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov:
- 01 Jun 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2013-001720-19).
- 21 May 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.